AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2020
Feb 29, 2020
33390_dirs_2020-02-28_0d595026-9a49-4bdf-adcf-68c0c49b1f09.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2020-02-26
Reporting Person: Birznieks Gunther (SVP, Business Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-26 | Common Stock | A | 30000 | — | Acquired | 177231 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-26 | Employee Stock Option (Right to Buy) | $11.32 | A | 70000 | Acquired | 2030-02-25 | Common Stock (70000) | Direct |
Footnotes
F1: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
F2: The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.